Jones Financial Companies
PVLA

Jones Financial Companies’s Palvella Therapeutics PVLA Stock Holding History

Jones Financial Companies’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5K Buy
226
+203
+883% +$24.6K ﹤0.01% 3287
2026
Q1 		$2.58K Buy
23
+17
+283% +$1.77K ﹤0.01% 4076
2025
Q4 		$628 Buy
6
+2
+50% +$171 ﹤0.01% 4118
2025
Q3 		$238 Buy
4
+1
+33% +$45 ﹤0.01% 4114
2025
Q2 		$66 Hold
3
– – ﹤0.01% 3967
2025
Q1 		$84 Hold
3
– – ﹤0.01% 3634
2024
Q4 		$36 Buy
+3
New +$47 ﹤0.01% 3389

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jones Financial Companies's PVLA Position: Q2 2026 in Review

Jones Financial Companies increased its Palvella Therapeutics (PVLA) stake by 883% in Q2 2026, buying an estimated $24.6K and bringing the position to 226 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3287.

Jones Financial Companies first reported a position in PVLA in Q4 2024 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Jones Financial Companies held 226 shares of Palvella Therapeutics worth $33.5K as of Q2 2026.
  • Jones Financial Companies bought 203 Palvella Therapeutics shares in Q2 2026, an estimated $24.6K.
  • Palvella Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3287 holding.
  • Jones Financial Companies first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.